The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $37.77, representing a -0.03% change from its previous close.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a notable 25% gain over the past week, gaining traction amid an executive departure. The announcement of COO Julianne Bruno’s exit could have influenced ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $86 and keeps a Buy rating on the shares. While Q1 earnings ...

Learn about Brink Tx as it raises $4 million to go beyond CRISPR with engineered recombinases in CAR T therapy.

Learn more about whether CRISPR Therapeutics AG or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ ...

Learn more about whether Amarin Corporation plc or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor ...

Learn More » CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties different from those of Vertex, though it has partnered with Vertex on certain programs.

CRISPR Therapeutics won its first regulatory approval a little over a year ago, and has compelling candidates in the pipeline. Of course, Vertex's success didn't happen overnight -- and the ...

The prospects for a one-time treatment that reduces the risk of heart disease for the rest of a person’s life just got ...

The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a ...